ELVN vs ENLV

Enliven Therapeutics, Inc. vs Enlivex Ltd. — Valuation Comparison 2026

ELVN

Biotechnology
Enliven Therapeutics, Inc.
Quality
3.8
out of 10
Value Trap
30
LOW
Price
$40.65
Last close
Models
10/13
Active
VS

ENLV

Biotechnology
Enlivex Ltd.
Quality
1.6
out of 10
Value Trap
12
SAFE
Price
$0.76
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ELVN Fair ValueELVN Upside ENLV Fair ValueENLV Upside
Bayesian DCF Intrinsic $13.43 -67.0% $0.20 -73.5%
Earnings Power Value Intrinsic $20.47 -53.8%
EROIC Spread Intrinsic $19.81 -55.2% $0.39 -51.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ELVN vs ENLV — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ELVN vs ENLV — Which Stock Is More Undervalued?

ELVN scores higher with a 3.8/10 quality rating vs ENLV's 1.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Enliven Therapeutics, Inc. (ELVN) and Enlivex Ltd. (ENLV) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ELVN currently trades at $40.65 with a QOC of 3.8/10, while ENLV trades at $0.76 with a QOC of 1.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).